H. D. Smith specialty subsidiary targets emerging biotechs; Cardium goes with Web-only sales outreach initially
H. D. Smith (Springfiled, IL), the largest privately held wholesaler-distributor in the US, has announced the deal with Cardium that it expects to be a model for future business for its recently formed specialty subsidiary, Smith Medical Partners (SMP). SMP will provide exclusive distribution and cold-chain logistics services for Excellagen (formulated bovine collagen), a wound care product approved for the management of diabetic foot ulcers and other dermal wounds. Cardium (San Diego) won approval from FDA late last year for the product, as a 510(k) medical device.
“We’re a full-service specialty distributor, licensed in all 50 states,” says Tom Doyle, VP of specialty services at SMP. “Our sweet spot, if you will, is emerging biotechs that need a flexible business model to achieve commercialization.” One example of this flexibility, he says, is a willingness to work with biotechs on their logistics issues even in clinical trials. So-called “hub” services, involving reimbursement, patient assistance and followup care, can also be contracted for. And while such hub and logistics services are often used for specialty products with limited markets, the Excellagen commercialization ultimately could reach a quite large market—Cardium says that foot ulcers affect upwards of 15% of diabetes patients, according to CDC data (putting the patient population in the low millions). Excellagen will have next-day delivery to physician offices nationwide through the distribution deal, says the company, which hopes to sell the product initially without an internal sales force.
Doyle adds that SMP has a dedicated facility in Wood Dale, but can also tap into resources and services available through its parent, which has eight distribution centers spread across the country.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.